Tulaven® is an effective solution for the metaphylaxis and treatment of bacterial pathogens involved in PRDC in all production phases (farrowing, nursery and finishing period).

Available in :

  • 100 ml
  • 250 ml

Product information

Easy to administrate (one shot): Its concentration dedicated exclusively to swine (25 mg/ml)
facilitate optimal administration in farrowing and weaning piglets with only one shot.

  • Optimal and Confident administration (peace of mind)
  • Reduced financial risk

Safe and high effective: Tulathromycin has unique effect due to its rapid and extensive
distribution into the lung tissue (target tissue of respiratory pathogens). Very long duration and
potential effect can be estimated based on plasma/lung ratio of tulathromycin in lungs. At 408 h
(17 days) post-tulathromycin administration, the lung/plasma ratio was >300 for both lung lobes
during the Pk/Pd study.
Tulathromycin provides at least 9 days of complete protection against A. pleuropneumoniae
during the challenge trial. Duration of treatment effect for 15 days was observed based on clinical
symptoms and examination of bronchoalveolar lavage (BAL) for H. parasuis and P. multocida.
Tulathromycin provide 14 days clinical effect for SRD associated with B. bronchiseptica based on
Day 14 clinical cure rate. Treatment effect of tulathromycin for minimally 13 days was established
following experimental infection of swine with Mycoplasma hyopneumoniae. Due to the very
low and stable MIC90 for M. hyo strains and Tulathromycin relatively high concentration in lungs
we can assume even longer effect.

Why choose Tulaven®?

Easy to administrate (one shot)

Safe and high effective

The Science behind

The control of the Clostridium perfringens type A associated diarrhea in suckling piglets by vaccination

D. Sperling, J. Vanhara, T. Jirasek, N. Guerra

The-control-of-the-C (1.44 MB)Download

Evaluation of the efficacy of a Clostridium perfringens type A/C toxoid vaccine for pigs under laboratory and field conditions

Sven Springer, Regine Fricke, Olaf Bastert, Jacqueline Finzel, Thomas Lindner, Tobias Theuß, Volker Florian and Daniel Sperling

Evaluation-of-the-ef (385.64 KB)Download

Shiga Toxin, Stx2e, Influences the Activity of Porcine Lymphocytes In Vitro

Daniel Sperling, Hana Stepanova, Han Smits, Anne-Kathrin Diesing and Martin Faldyna

Shiga-Toxin-Stx2e-In (1.61 MB)Download

Influence of host factors on the secretion of STX2E by shigatoxin – producing Escherichia Coli (STEC) field strains from swine

Sander Van hoorde, Bert Devriendt, Daniel Sperling, H. Xiaohua, Eric Cox

Influence-of-host-fa (1.38 MB)Download

Effect of the vaccination against Shiga toxin 2e in a farm with history of oedema disease, caused by atypical Escherichia coli producing Shiga toxin (STEC)

Daniel Sperling, Naomi Isaka, Hamadi Karembe, Jonas Vanhara, Josef Vinduska, Nicol Strakova, Alzbeta Kalova, Ivana Kolackova, Renata Karpiskova

Effect-of-the-vaccin (319.87 KB)Download

Comparative analysis of STX2E secretion in shiga toxin – producing Escherichia Coli (STEC) field strains from swine

Sander Van hoorde, Bert Devriendt, Daniel Sperling, Eric Cox

Comparative-analysis (1.82 MB)Download

Post-antibiotic effect of marbofloxacin, enrofloxacin and amoxicillin against selected respiratory pathogens of pigs

Katerina Nedbalcova, Monika Zouharova, Daniel Sperling

Post-antibiotic-effe (191.93 KB)Download

From one country to another, product lines are adapted to local demand and regulatory requirements. For further information, please take a look at the CEVA Santé Animale site for your country. Warning: the information provided on the products depends on national registrations. Access to technical information is restricted to authorised persons.